-
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres (Y-90 microsphere injection) in mainland China for the treatment of malignant liver tumors. The product received approval in February 2022 for patients with unresectable liver metastases from colorectal cancer who have failed standard therapy. Product…
-
Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China
•
China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA) for its drug OT-401 (fluocinolone intravitreal implant) for treating chronic non-infectious uveitis. This marks a significant milestone as the first new drug approved in China based on real-world data (RWD), accelerating its commercialization by approximately…
-
AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a strategic partnership with the municipal government of Qingdao, Shandong province. The collaboration encompasses the establishment of a manufacturing and supply base, regional headquarters, a rare disease innovation center, a life science innovation park, and an…
-
CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance
•
China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for treating gastrointestinal stromal tumors (GIST), has been included in Taiwan’s National Health Insurance, effective June 1, 2022. Drug Approval and BackgroundAvapritinib received approval in Taiwan under the trade name TaiShiWei in 2021 for adult patients…
-
Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions
•
Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy industry, has reportedly secured RMB 100 million (USD 14.97 million) in a Series B financing round. The funding, led by Eight Roads Capital and joined by Shenzhen Jiufite Private Equity Investment Management and Juke Investment,…
-
Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development
•
China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation vaccines and therapies, has completed a Series A financing round exceeding RMB 280 million (USD 41.8 million). The round was led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare…
-
Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits
•
China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the European Union (EU) for its monkeypox virus nucleic acid detection kit (fluorescent PCR method) and novel coronavirus (SARS-CoV-2) antigen detection kit. Monkeypox Virus Detection KitThe monkeypox virus nucleic acid detection kit uses a real-time fluorescent…
-
SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA
•
China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical Products Administration (NMPA) for its generic versions of blonanserin, paracetamol, mannitol, and levofloxacin. Notably, the generic versions of blonanserin and paracetamol are the first of their kind to be approved in China. Drug Details and…
-
Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round
•
Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has reportedly secured RMB 100 million (USD 14.93 million) in a Series A financing round. The funding was led by Apricot Capital and Industrial Securities Capital, with participation from Dalton Venture, Bangming Capital, and HiMed Angle…
-
Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan
•
Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology Parks Corporation have announced a co-incubation plan aimed at promoting and incubating startups in the fields of infectious diseases and immunology. Collaboration ObjectivesThe initiative seeks to accelerate the translation of cutting-edge science into innovative treatments,…
-
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
•
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801) has received approval for a new indication of its PD-1 inhibitor Tyvyt (sintilimab) for the treatment of first-line esophageal squamous cell carcinoma (ESCC). This marks the fifth indication approval for the drug in China. Drug…
-
Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion
•
Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to USD 100 million in a Series B financing round. The funding was co-led by AstraZeneca CICC Medical Fund and YF Capital, with participation from C-Bridge Capital, SDIC China Merchants Capital, and 5Y Capital. The proceeds…
-
Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect airway ultrasound needle in mainland China. The product is designed for use in transbronchial needle aspiration biopsies guided by endoscopic ultrasonography, offering a significant advancement in lung cancer diagnosis. Product Innovation and AdvantagesThe Expect airway…
-
Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion
•
Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly secured close to RMB 100 million (USD 14.96 million) in a Series A financing round co-led by Oriza Seed and Apricot Capital. The proceeds will be directed toward advancing technology platforms in proteomics and spatialomics,…
-
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
•
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New Drug (IND) filing for CM369, a monoclonal antibody targeting C-C chemokine receptor 8 (CCR8), has been accepted for review by the National Medical Products Administration (NMPA). This potential first-in-class drug is designed to enhance tumor-targeted…
-
Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion
•
Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly secured RMB 100 million in a Series A financing round. The funding was led by Shenzhen Guochuang Zhiyuan Private Equity Fund Management, Shenzhen Ruihai Private Equity Investment Fund Management, VDO Biotech, Shenzhen Qianhai Zhouyu Investment…
-
Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a global multi-center Phase III clinical study for its drug candidate HLX14, a biosimilar of Amgen’s Prolia/Xgeva (denosumab). The study targets the treatment of postmenopausal osteoporosis in women at high risk of fracture. Clinical Trial DesignThe…
-
Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study
•
China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February last year, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib clinical study of its chimeric antigen receptor (CAR)-T cell therapy C-CAR039 in patients with relapsed or refractory…
-
Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial
•
Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from the US FDA for its subsidiary Cellenkos’ pipeline candidate CM0804. The FDA clearance allows Cellenkos to initiate a Phase Ib, open-label study for CM0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who…
-
Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent
•
Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments, has secured close to RMB 100 million (USD 14.9 million) in a Series B financing round. The funding, led by Topping Capital and Guolian Group, will support a regulatory clinical study for its gastric bypass…
